Charles River Laboratories Intl ((CRL)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles River Laboratories International’s latest earnings call struck a cautiously optimistic tone, as management balanced solid 2025 execution with clear acknowledgment of 2026 headwinds. Revenue and EPS landed at the high end of earlier guidance, DSA bookings and backlog improved, and strategic moves aim to shore up margins, even as organic growth, free cash flow, and near‑term profitability face pressure.
Revenue and EPS Land at Top of Guidance
Charles River reported FY 2025 revenue of $4.02 billion and non‑GAAP EPS of $10.28, essentially flat versus $10.32 a year earlier. Management underscored that both metrics finished at the upper end of the ranges laid out in November, signaling disciplined execution in a choppy demand environment.
DSA Bookings and Backlog Show Early Demand Turn
The Discovery and Safety Assessment segment posted a Q4 2025 net book‑to‑bill of 1.12x on $665 million of net bookings, an encouraging improvement. Backlog ticked up to $1.86 billion from $1.8 billion at the end of Q3, suggesting better visibility and momentum heading into 2026 despite near‑term revenue declines.
Strategic Deals to Secure NHP Supply and Expand Testing
Management highlighted the completed acquisition of KF Cambodia to secure non‑human primate supply and lower sourcing costs, reducing a key operational risk. The planned PathoQuest acquisition, expected to close soon, is designed to bolster NAMS and biologics testing, with a modest revenue contribution anticipated in 2026.
Guided EPS Growth and Margin Expansion in 2026
For 2026, Charles River guided non‑GAAP EPS to $10.70–$11.20, implying about 4%–9% growth despite flat to slightly negative organic revenue. The company expects consolidated operating margin to expand by 20–50 basis points from 2025’s 19.8%, banking on cost savings and M&A benefits to offset demand and mix headwinds.
KF Deal Poised to Boost EPS and Margins
The KF Cambodia acquisition is expected to contribute roughly $0.25 to EPS in 2026, a benefit already embedded in guidance. Management also sees the deal lifting consolidated operating margin by more than 50 basis points, and DSA margin by over 100 basis points in 2026, with accretion building toward about $0.60 by 2027.
Manufacturing and Microbial Solutions Stand Out
Manufacturing Solutions delivered margin improvement, with Q4 operating margin at 32.1%, up 340 basis points, and full‑year margin at 28.8%, up 140 basis points. Microbial Solutions showed robust growth across EndoSafe, Celsis, and Accugenix, while biologics testing returned to modest growth in Q4 after earlier client‑specific pressures.
Cost Actions and Tighter Capital Management
The company expects at least $100 million of incremental annual cost savings in 2026 versus 2025, contributing to more than $300 million of cumulative annualized savings from initiatives over the last three years. Net interest expense is forecast to ease to $95 million–$100 million from $102.1 million, with leverage around 2.0x, giving management room to maneuver.
Balance Sheet Positioned for Deals and Debt Paydown
Charles River ended with roughly $2.1 billion of debt, about 70% at fixed rates, providing rate visibility. The company plans to fund the KF and PathoQuest transactions totaling over $500 million, prioritize debt repayment, maintain financing flexibility, and hold 2026 capex near $200 million, about 5% of revenue.
Organic Revenue Declines Broad‑Based in 2025
Q4 2025 revenue was $994.2 million, down organically 2.6% year over year, while full‑year organic revenue declined 1.6%. All three segments reported organic declines in the quarter, underscoring the cyclical and funding‑sensitive backdrop across the company’s end markets.
DSA Volume Slump and Margin Compression
DSA revenue fell to $591.6 million in Q4, an organic decline of 3.3%, with full‑year DSA revenue down 2.6%. Segment operating margin dropped sharply to 20.1% in Q4, down 460 basis points, and to 24.2% for the year, hurt by lower volumes, higher staffing, and elevated NHP sourcing costs.
Elevated NHP Costs and RMS Timing Hit Growth
Rising non‑human primate study starts forced Charles River to buy animals on the open market at higher prices, squeezing margins into late 2025 and early 2026. Timing issues around RMS NHP revenue and shipment acceleration weighed on Q4 and are expected to be a roughly 200‑basis‑point drag on RMS growth in 2026.
Q1 2026 Set for Earnings and Margin Dip
Management warned that Q1 2026 will be a low point, with operating margin guided to the mid‑teens and non‑GAAP EPS down by a high‑teens percentage year over year. Discrete headwinds include about $0.15 of accelerated stock‑based compensation tied to the CEO transition and roughly $10 million timing effects in each of RMS and Manufacturing.
CDMO Client Loss Weighs on Manufacturing Revenue
The loss of a commercial cell therapy CDMO client reduced revenue by approximately $20 million–$25 million in 2025, pressuring the Manufacturing Solutions top line. As a result, Manufacturing posted organic declines of 2.1% in Q4 and 1.6% for the full year, partially offsetting strength in other sub‑segments.
Free Cash Flow to Step Down in 2026
Free cash flow is projected to fall to $375 million–$400 million in 2026, down from $518.5 million in 2025, despite stable capex. The decline is driven largely by higher performance‑based cash bonuses paid in early 2026 and deferred compensation related to the outgoing CEO, temporarily tightening cash generation.
Divestiture Plans Introduce Execution Risk
Charles River is negotiating the sale of businesses representing about 7% of 2025 revenue, with completion targeted by 2026. Management cautioned that both timing and ultimate proceeds remain uncertain until transactions are finalized, adding an extra layer of near‑term portfolio and earnings unpredictability.
NAMS and AI Progressing, but Impact Still Limited
The company is investing in next‑generation modalities and AI, including Retrogenix, virtual control groups, and PathoQuest’s sequencing capabilities. However, management stressed that regulatory, validation, and data hurdles mean adoption in regulated safety assessment will be gradual, with no material near‑term displacement of core in‑vivo work.
2026 Outlook: Modest Growth, Margin Lift, Uneven Start
For 2026, Charles River expects organic revenue to range from down about 1% to flat, with reported revenue flat to up 1.5% helped by foreign‑exchange tailwinds. The company sees consolidated margin expanding 20–50 basis points, EPS growing 4%–9%, RMS and DSA roughly flat to slightly down organically, and Manufacturing returning to low‑single‑digit growth, with free cash flow easing and Q1 representing the trough.
Charles River’s earnings call laid out a mixed but improving picture, with strong cost control, strategic M&A, and resilient Microbial and Manufacturing margins offsetting volume softness and near‑term cash and EPS pressure. For investors, the story hinges on DSA demand follow‑through, successful integration of KF and PathoQuest, and execution on divestitures as the company steers toward modest growth and margin expansion in 2026.